Sang Mok Lee agreed to acquire 46% of stake in BiocurePharm Corporation from Biocure Technology Inc. (CNSX:CURE) for CAD 0.27 million on December 16, 2022. Biocure Technology will retain its minority interest in BPK. Following completion of the restructuring Transaction, Lee would resign from the Board of the Company and as its Chief Executive Officer.

Transaction is subject to the approval of Biocure Technology's shareholders As of January 13, 2023, Biocure Technology will conduct the special meeting to the shareholders to approve this transaction. As of February 17, 2023, Biocure Technology shareholders approved the deal.